Abstract
Targeted drug delivery systems (TDDS) represent one of the most promising advancements in cancer treatment. These systems aim to improve the therapeutic efficacy of anticancer drugs while minimizing their toxicity to healthy tissues. Recent developments in TDDS have led to the design of nanoparticles, conjugates, and biologically active agents that enhance the precision of drug delivery. This article reviews the latest progress in targeted drug delivery for cancer treatment, emphasizing the types of nanoparticles used, their mechanisms, clinical applications, and challenges faced in translating these systems from laboratory research to clinical settings. Through a deeper understanding of tumor biology, researchers have refined strategies to achieve selective and controlled drug release, potentially revolutionizing cancer therapy.

This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2020 Dr. John Doe (Author)